

---

**285 Paper alert**

Arcadio Chonn, Barbara Demeneix & Rosanne Orr

---

**288 Patent alert**

Debabrata Banerjee, David Curiel & Jesus Gomez-Navarro

---

**294 Web alert**

Alan Boddy & Karen Palmer

---

**Oligonucleotides - from design to the clinic**

Edited by Kirk Field & C Frank Bennett

---

**296 C Frank Bennett**

Editorial overview

**297 Alan M Gewirtz**

Oligonucleotide therapeutics: Clothing the emperor

**307 Paul F Torrence**

2-5A-antisense chimeras: Inhibitors of respiratory syncytial virus infection

**316 John J Rossi**

The application of ribozymes to HIV infection

**323 A Kirk Field**

Oligonucleotides as inhibitors of human immunodeficiency virus

**332 Bruce Yacyshyn, MB Bowen-Yacyshyn & William Shanahan**

The clinical experience of antisense therapy to ICAM-1 in Crohn's disease

**336 Siew Peng Ho & Paul R Hartig**

Antisense oligonucleotides for target validation in the CNS

**344 Radhakrishnan P Iyer, Arlene Roland, Wen Zhou & Krishna Ghosh**

Modified oligonucleotides - synthesis, properties and applications

**359 C Frank Bennett & Lex M Cowser**

Application of antisense oligonucleotides for gene functionalization and target validation

**372 Jon T Holmlund, Brett P Monia, T Jesse Kwoh & F Andrew Dorr**

Towards antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development

**386 Yoon S Cho-Chung, Yun Gyu Park & Youl Nam Lee**

Oligonucleotides as transcription factor decoys

**393 Kai Li, Jia Zhang, Pierre Sirois & Yinghe Hu**

Technology evaluation: ISIS-3521

**399 Rosanne M Orr**

Technology evaluation: Leukemia therapy, University of Pennsylvania

**404 Debabrata Banerjee**

Technology evaluation: G-3139

**409 Errata**

---